{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T01:34:26Z","timestamp":1792892066784,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Leishmaniasis remains a serious public health problem in several parts of the developing world. Effective prophylactic measurements are hampered by imprecise comprehension of different aspects of the disease, including its immunoregulation. A better comprehension of immunoregulation in human VL may be useful both for designing and evaluating immunoprophylaxis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To explore immunoregulatory mechanisms, 20 visceral leishmaniasis (VL) patients were evaluated during active disease and at different periods up to one year after treatment determining their plasma cytokine levels, clinical parameters (palpable spleen and liver) and antibody levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Elevated plasma levels of IFN-\u03b3 and of IL-12 p40 were observed during active disease, significantly decreasing after treatment whereas in vitro Leishmania antigen-stimulated IFN-\u03b3 production by PBMC exhibited an inverse pattern being low during disease and increasing steadily thereafter. Absence of IFN-\u03b3 activity is a hallmark of VL. The main candidate for blunting IFN-\u03b3 activity is IL-10, a cytokine highly elevated in plasma with sharp decrease after treatment. Activity of IL-10 is inferred by high levels of anti-Leishmania specific IgG1 and IgG3. TGF-\u03b2 had elevated total, but not of active, levels lessening the likelihood of being the IFN-\u03b3 counterpart. Spleen or liver size presented a steady decrease but return to normal values at only 120 days after treatment. Anti-Leishmania IgG (total and subclasses) levels and DTH or Leishmania-stimulated lymphocyte proliferation conversion to positive also present a slow decrease after treatment. IL-6 plasma levels were elevated in only a few patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Taken together our results suggest that IFN-\u03b3 and IL-10 are the molecules most likely involved in determining fate of disease. After treatment, there is a long delay before the immune profile returns to normal what precludes using plasma cytokine levels as criteria of cure as simpler clinical evaluations, as a palpable spleen or liver, can be used.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1471-2334-5-113","type":"journal-article","created":{"date-parts":[[2005,12,20]],"date-time":"2005-12-20T07:13:47Z","timestamp":1135062827000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":124,"title":["Balance of IL-10 and Interferon-\u03b3 plasma levels in human visceral leishmaniasis: Implications in the pathogenesis"],"prefix":"10.1186","volume":"5","author":[{"given":"Arlene","family":"Caldas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cec\u00edlia","family":"Favali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorlene","family":"Aquino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Vinhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"van Weyenbergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e1udia","family":"Brodskyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackson","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoel","family":"Barral-Netto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldina","family":"Barral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,12,19]]},"reference":[{"key":"261_CR1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1590\/S0100-879X1998000100020","volume":"31","author":"A Ribeiro-de-Jesus","year":"1998","unstructured":"Ribeiro-de-Jesus A, Almeida RP, Lessa H, Bacellar O, Carvalho EM: Cytokine profile and pathology in human leishmaniasis. Braz J Med Biol Res. 1998, 31: 143-148. 10.1590\/S0100-879X1998000100020.","journal-title":"Braz J Med Biol Res"},{"key":"261_CR2","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1172\/JCI112209","volume":"76","author":"EM Carvalho","year":"1985","unstructured":"Carvalho EM, Badaro R, Reed SG, Jones TC, Johnson WDJ: Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest. 1985, 76: 2066-2069.","journal-title":"J Clin Invest"},{"key":"261_CR3","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1128\/iai.33.2.498-500.1981","volume":"33","author":"EM Carvalho","year":"1981","unstructured":"Carvalho EM, Teixeira RS, Johnson WDJ: Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infect Immun. 1981, 33: 498-500.","journal-title":"Infect Immun"},{"key":"261_CR4","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1172\/JCI113969","volume":"83","author":"EM Carvalho","year":"1989","unstructured":"Carvalho EM, Bacellar O, Barral A, Badaro R, Johnson WDJ: Antigen-specific immunosuppression in visceral leishmaniasis is cell mediated. J Clin Invest. 1989, 83: 860-864.","journal-title":"J Clin Invest"},{"key":"261_CR5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/infdis\/165.3.535","volume":"165","author":"EM Carvalho","year":"1992","unstructured":"Carvalho EM, Barral A, Pedral-Sampaio D, Barral-Netto M, Badaro R, Rocha H, Johnson WDJ: Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J Infect Dis. 1992, 165: 535-540.","journal-title":"J Infect Dis"},{"key":"261_CR6","doi-asserted-by":"crossref","first-page":"908","DOI":"10.4049\/jimmunol.138.3.908","volume":"138","author":"DL Sacks","year":"1987","unstructured":"Sacks DL, Lal SL, Shrivastava SN, Blackwell J, Neva FA: An analysis of T cell responsiveness in Indian kala-azar. J Immunol. 1987, 138: 908-913.","journal-title":"J Immunol"},{"key":"261_CR7","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1006\/cyto.2000.0694","volume":"12","author":"O Bacellar","year":"2000","unstructured":"Bacellar O, D'Oliveira AJ, Jeronimo S, Carvalho EM: IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. Cytokine. 2000, 12: 1228-1231. 10.1006\/cyto.2000.0694.","journal-title":"Cytokine"},{"key":"261_CR8","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1086\/320994","volume":"184","author":"A Hailu","year":"2001","unstructured":"Hailu A, Menon JN, Berhe N, Gedamu L, Hassard TH, Kager PA, Olobo J, Bretscher PA: Distinct immunity in patients with visceral leishmaniasis from that in subclinically infected and drug-cured people: implications for the mechanism underlying drug cure. J Infect Dis. 2001, 184: 112-115. 10.1086\/320994.","journal-title":"J Infect Dis"},{"key":"261_CR9","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/infdis\/171.4.992","volume":"171","author":"S Sundar","year":"1995","unstructured":"Sundar S, Rosenkaimer F, Lesser ML, Murray HW: Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis. J Infect Dis. 1995, 171: 992-996.","journal-title":"J Infect Dis"},{"key":"261_CR10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.4269\/ajtmh.2004.71.561","volume":"71","author":"A Hailu","year":"2004","unstructured":"Hailu A, van der Poll T, Berhe N, Kager PA: Elevated plasma levels of interferon (IFN)-gamma, IFN-gamma inducing cytokines, and IFN-gamma inducible CXC chemokines in visceral leishmaniasis. Am J Trop Med Hyg. 2004, 71: 561-567.","journal-title":"Am J Trop Med Hyg"},{"key":"261_CR11","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1093\/infdis\/168.4.986","volume":"168","author":"P Cenini","year":"1993","unstructured":"Cenini P, Berhe N, Hailu A, McGinnes K, Frommel D: Mononuclear cell subpopulations and cytokine levels in human visceral leishmaniasis before and after chemotherapy. J Infect Dis. 1993, 168: 986-993.","journal-title":"J Infect Dis"},{"key":"261_CR12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1590\/S0036-46651998000100007","volume":"40","author":"IM de Medeiros","year":"1998","unstructured":"de Medeiros IM, Castelo A, Salomao R: Presence of circulating levels of interferon-gamma, interleukin-10 and tumor necrosis factor-alpha in patients with visceral leishmaniasis. Rev Inst Med Trop Sao Paulo. 1998, 40: 31-34.","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"261_CR13","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1006\/cyto.1995.0088","volume":"7","author":"E Cillari","year":"1995","unstructured":"Cillari E, Vitale G, Arcoleo F, D'Agostino P, Mocciaro C, Gambino G, Malta R, Stassi G, Giordano C, Milano S, et al: In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis. Cytokine. 1995, 7: 740-745. 10.1006\/cyto.1995.0088.","journal-title":"Cytokine"},{"key":"261_CR14","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.4049\/jimmunol.152.12.5949","volume":"152","author":"EM Carvalho","year":"1994","unstructured":"Carvalho EM, Bacellar O, Brownell C, Regis T, Coffman RL, Reed SG: Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J Immunol. 1994, 152: 5949-5956.","journal-title":"J Immunol"},{"key":"261_CR15","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.4049\/jimmunol.170.5.2613","volume":"170","author":"KR Gantt","year":"2003","unstructured":"Gantt KR, Schultz-Cherry S, Rodriguez N, Jeronimo SM, Nascimento ET, Goldman TL, Recker TJ, Miller MA, Wilson ME: Activation of TGF-beta by Leishmania chagasi: importance for parasite survival in macrophages. J Immunol. 2003, 170: 2613-2620.","journal-title":"J Immunol"},{"key":"261_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/0090-1229(95)90144-2","volume":"77","author":"T van der Poll","year":"1995","unstructured":"van der Poll T, Zijlstra EE, Mevissen M: Interleukin 6 during active visceral leishmaniasis and after treatment. Clin Immunol Immunopathol. 1995, 77: 111-114. 10.1016\/0090-1229(95)90144-2.","journal-title":"Clin Immunol Immunopathol"},{"key":"261_CR17","doi-asserted-by":"crossref","first-page":"522","DOI":"10.4269\/ajtmh.1997.56.522","volume":"56","author":"S Sundar","year":"1997","unstructured":"Sundar S, Reed SG, Sharma S, Mehrotra A, Murray HW: Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am J Trop Med Hyg. 1997, 56: 522-525.","journal-title":"Am J Trop Med Hyg"},{"key":"261_CR18","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1093\/infdis\/163.4.853","volume":"163","author":"M Barral-Netto","year":"1991","unstructured":"Barral-Netto M, Badaro R, Barral A, Almeida RP, Santos SB, Badaro F, Pedral-Sampaio D, Carvalho EM, Falcoff E, Falcoff R: Tumor necrosis factor (cachectin) in human visceral leishmaniasis. J Infect Dis. 1991, 163: 853-857.","journal-title":"J Infect Dis"},{"key":"261_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1084\/jem.169.1.59","volume":"169","author":"FP Heinzel","year":"1989","unstructured":"Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM: Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med. 1989, 169: 59-72. 10.1084\/jem.169.1.59.","journal-title":"J Exp Med"},{"key":"261_CR20","doi-asserted-by":"publisher","first-page":"7011","DOI":"10.1073\/pnas.88.16.7011","volume":"88","author":"FP Heinzel","year":"1991","unstructured":"Heinzel FP, Sadick MD, Mutha SS, Locksley RM: Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc Natl Acad Sci U S A. 1991, 88: 7011-7015.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"261_CR21","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.4049\/jimmunol.147.9.3149","volume":"147","author":"P Scott","year":"1991","unstructured":"Scott P: IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J Immunol. 1991, 147: 3149-3155.","journal-title":"J Immunol"},{"key":"261_CR22","first-page":"1485","volume":"22","author":"M Barral-Netto","year":"1989","unstructured":"Barral-Netto M, Diez R, Badaro R, Sampaio D, Barral A, Carvalho EM, Falcoff E: Serum interferon activity of patients with leishmaniasis. Braz J Med Biol Res. 1989, 22: 1485-1487.","journal-title":"Braz J Med Biol Res"},{"key":"261_CR23","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1126\/science.1636092","volume":"257","author":"M Barral-Netto","year":"1992","unstructured":"Barral-Netto M, Barral A, Brownell CE, Skeiky YA, Ellingsworth LR, Twardzik DR, Reed SG: Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science. 1992, 257: 545-548.","journal-title":"Science"},{"key":"261_CR24","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1073\/pnas.90.8.3442","volume":"90","author":"A Barral","year":"1993","unstructured":"Barral A, Barral-Netto M, Yong EC, Brownell CE, Twardzik DR, Reed SG: Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis. Proc Natl Acad Sci U S A. 1993, 90: 3442-3446.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"261_CR25","first-page":"947","volume":"147","author":"A Barral","year":"1995","unstructured":"Barral A, Teixeira M, Reis P, Vinhas V, Costa J, Lessa H, Bittencourt AL, Reed S, Carvalho EM, Barral-Netto M: Transforming growth factor-beta in human cutaneous leishmaniasis. Am J Pathol. 1995, 147: 947-954.","journal-title":"Am J Pathol"},{"key":"261_CR26","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1126\/science.1636090","volume":"257","author":"PA Bretscher","year":"1992","unstructured":"Bretscher PA, Wei G, Menon JN, Bielefeldt-Ohmann H: Establishment of stable, cell-mediated immunity that makes \"susceptible\" mice resistant to Leishmania major. Science. 1992, 257: 539-542.","journal-title":"Science"},{"key":"261_CR27","doi-asserted-by":"crossref","first-page":"281","DOI":"10.4049\/jimmunol.147.1.281","volume":"147","author":"M Barral-Netto","year":"1991","unstructured":"Barral-Netto M, Barral A, Santos SB, Carvalho EM, Badaro R, Rocha H, Reed SG, Johnson WDJ: Soluble IL-2 receptor as an agent of serum-mediated suppression in human visceral leishmaniasis. J Immunol. 1991, 147: 281-284.","journal-title":"J Immunol"},{"key":"261_CR28","first-page":"14","volume":"64","author":"EM el Amin","year":"1986","unstructured":"el Amin EM, Wright EP, Vlug A: Characterization of the humoral immune response in Sudanese leishmaniasis: specific antibody detected by class- and subclass-specific reagents. Clin Exp Immunol. 1986, 64: 14-19.","journal-title":"Clin Exp Immunol"},{"key":"261_CR29","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1365-2249.1994.tb06526.x","volume":"95","author":"AM Elassad","year":"1994","unstructured":"Elassad AM, Younis SA, Siddig M, Grayson J, Petersen E, Ghalib HW: The significance of blood levels of IgM, IgA, IgG and IgG subclasses in Sudanese visceral leishmaniasis patients. Clin Exp Immunol. 1994, 95: 294-299.","journal-title":"Clin Exp Immunol"},{"key":"261_CR30","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1128\/IAI.72.2.863-870.2004","volume":"72","author":"R Ravindran","year":"2004","unstructured":"Ravindran R, Anam K, Bairagi BC, Saha B, Pramanik N, Guha SK, Goswami RP, Banerjee D, Ali N: Characterization of immunoglobulin G and its subclass response to Indian kala-azar infection before and after chemotherapy. Infect Immun. 2004, 72: 863-870. 10.1128\/IAI.72.2.863-870.2004.","journal-title":"Infect Immun"},{"key":"261_CR31","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0035-9203(03)90092-7","volume":"97","author":"B Buchetont","year":"2003","unstructured":"Buchetont B, El-Safi SH, Hammad A, Kheir MM, Eudes N, Mirgani A, Dessein AJ, Mary C: Antileishmanial antibodies in an outbreak of visceral leishmaniasis in eastern Sudan: high antibody responses occur in resistant subjects and are not predictive of disease. Trans R Soc Trop Med Hyg. 2003, 97: 463-468. 10.1016\/S0035-9203(03)90092-7.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"261_CR32","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1046\/j.1365-2249.1998.00752.x","volume":"114","author":"M Chatterjee","year":"1998","unstructured":"Chatterjee M, Basu K, Basu D, Bannerjee D, Pramanik N, Guha SK, Goswami RP, Saha SK, Mandal C: Distribution of IgG subclasses in antimonial unresponsive Indian kala-azar patients. Clin Exp Immunol. 1998, 114: 408-413. 10.1046\/j.1365-2249.1998.00752.x.","journal-title":"Clin Exp Immunol"},{"key":"261_CR33","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1128\/CDLI.6.2.231-235.1999","volume":"6","author":"K Anam","year":"1999","unstructured":"Anam K, Afrin F, Banerjee D, Pramanik N, Guha SK, Goswami RP, Gupta PN, Saha SK, Ali N: Immunoglobulin subclass distribution and diagnostic value of Leishmania donovani antigen-specific immunoglobulin G3 in Indian kala-azar patients. Clin Diagn Lab Immunol. 1999, 6: 231-235.","journal-title":"Clin Diagn Lab Immunol"},{"key":"261_CR34","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1590\/S0100-879X2004000100018","volume":"37","author":"ME Gama","year":"2004","unstructured":"Gama ME, Costa JM, Pereira JC, Gomes CM, Corbett CE: Serum cytokine profile in the subclinical form of visceral leishmaniasis. Braz J Med Biol Res. 2004, 37: 129-136. 10.1590\/S0100-879X2004000100018.","journal-title":"Braz J Med Biol Res"},{"key":"261_CR35","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S1471-4922(03)00139-9","volume":"19","author":"O Garraud","year":"2003","unstructured":"Garraud O, Perraut R, Riveau G, Nutman TB: Class and subclass selection in parasite-specific antibody responses. Trends Parasitol. 2003, 19: 300-304. 10.1016\/S1471-4922(03)00139-9.","journal-title":"Trends Parasitol"},{"key":"261_CR36","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/0952-7915(95)80046-8","volume":"7","author":"JE de Vries","year":"1995","unstructured":"de Vries JE, Carballido JM, Sornasse T, Yssel H: Antagonizing the differentiation and functions of human T helper type 2 cells. Curr Opin Immunol. 1995, 7: 771-778. 10.1016\/0952-7915(95)80046-8.","journal-title":"Curr Opin Immunol"},{"key":"261_CR37","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1093\/infdis\/161.5.988","volume":"161","author":"P Pisa","year":"1990","unstructured":"Pisa P, Gennene M, Soder O, Ottenhoff T, Hansson M, Kiessling R: Serum tumor necrosis factor levels and disease dissemination in leprosy and leishmaniasis. J Infect Dis. 1990, 161: 988-991.","journal-title":"J Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-5-113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-5-113\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-5-113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-5-113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T23:11:35Z","timestamp":1683328295000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-5-113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["261"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-5-113","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12]]},"assertion":[{"value":"10 August 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"113"}}